Author:
Cohen Stanley,Fleischmann Roy
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference14 articles.
1. ‘Go upstream, young man’: lessons learnt from the p38 saga;Hammaker;Ann Rheum Dis,2010
2. MAPKs and their relevance to arthritis and inflammation;Thalhamer;Rheumatology,2008
3. A randomized, double-blind, placebo controlled phase 2 study of an oral p38a MAPK inhibitor, SCIO-469, in patients with active rheumatoid arthritis [abstract 715];Genovese;Arthritis Rheum,2008
4. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial;Schreiber;Clin Gastroenterol Hepatol,2006
5. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis;Cohen;Arthritis Rheum,2009
Cited by
86 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献